Oral Antibiotics for Step-down Therapy from Meropenem

Selection Criteria for Step-down Therapy

Susceptibility testing is essential before transitioning from meropenem to ensure the chosen oral agent will be effective against the identified pathogen 1
Clinical improvement should be evident before switching to oral therapy, including improvement in symptoms, afebrile status, decreasing white blood cell count, and functioning gastrointestinal tract with adequate oral intake 3, 4

For Extended-Spectrum Beta-Lactamase (ESBL) producing organisms, fluoroquinolones (if susceptible) such as ciprofloxacin 400-750 mg PO q12h or levofloxacin 750 mg PO daily may be used 2
For ESBL producing organisms, trimethoprim-sulfamethoxazole 160/800 mg PO q12h (especially for urinary tract infections) may be used 2
For complicated intra-abdominal infections, fluoroquinolones plus metronidazole for anaerobic coverage may be used 4, 5
For urinary tract infections, fosfomycin 3g PO as a single dose or every other day (for susceptible organisms) may be used 6, 7

For multi-drug resistant organisms, linezolid 600 mg PO q12h is effective for vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) 6, 7
For Pseudomonas aeruginosa, ciprofloxacin 750 mg PO q12h is the preferred oral option if susceptible 5, 8

Avoid fluoroquinolones if there is known resistance or if the patient has risk factors for fluoroquinolone-resistant organisms 2
Do not use macrolides alone for step-down therapy from meropenem as they have limited gram-negative coverage 9
Consider continuing IV therapy if the pathogen shows resistance to available oral options, the infection site has poor penetration by oral antibiotics, or the patient has severe immunocompromise 1, 4, 6
Duration of therapy should be individualized based on infection site, source control, underlying comorbidities, and initial response to therapy 6

Identify the causative pathogen and obtain susceptibility results 8
Assess clinical improvement (temperature, WBC, symptoms) 3
Select oral agent based on pathogen susceptibility, site of infection, and patient factors (allergies, renal/hepatic function) 2, 4, 8
Complete the appropriate duration of total antibiotic therapy 1, 3, 6